Dinoges-EV Tablet

About Dinoges-EV 2 mg + 2 mg Tablet

Dinoges-EV is a combined oral contraceptive tablet containing dienogest and estradiol valerate, used to prevent pregnancy and to treat heavy menstrual bleeding in women without organic pathology who choose this method.

What is Dinoges-EV 2 mg + 2 mg Tablet?

Dinoges-EV is a female sex hormone tablet that combines a progestin and an estrogen. It works mainly by stopping the release of an egg from the ovary, which prevents pregnancy. It is also used for heavy menstrual bleeding in women who have no underlying organic cause and who choose an oral contraceptive as their birth control method. Dinoges-EV comes as a 2 mg + 2 mg tablet in a 28 tablet pack. The effectiveness in women with a high body mass index has not been evaluated. The doctor will decide if it is suitable for you.

Uses of Dinoges-EV

Dinoges-EV is used by women to prevent pregnancy. It is also used to treat heavy menstrual bleeding in women who have no organic disease causing the bleeding and who choose to use an oral contraceptive for birth control. It is a combined hormonal contraceptive. Your doctor will assess whether this method is right for you.

How to use Dinoges-EV

Take the tablet by mouth every day at the same time, following the order printed on the blister pack. Do not skip a tablet or delay taking it by more than the allowed time. If you forget a tablet, read the pack instructions or ask your pharmacist. The doctor decides the dose and how long you should take it. Do not change the schedule on your own.

Side effects of Dinoges-EV

Common side effects include headache, including migraine, breast pain, menstrual disorders, nausea or vomiting, acne, mood changes and weight gain. These were reported in clinical trials. Tell your doctor if any side effect bothers you or does not go away. Seek medical help right away if you have signs of a blood clot, such as leg pain or swelling, sudden shortness of breath or chest pain.

Safety and precautions

Do not use Dinoges-EV if you have a high risk of blood clots in arteries or veins, undiagnosed abnormal uterine bleeding, or breast cancer or other cancers that are sensitive to estrogens or progestins. Stop the tablet if a thrombotic event occurs. Stop it at least four weeks before and through two weeks after major surgery. Do not start it earlier than four weeks after delivery if you are not breastfeeding. Stop if jaundice occurs. Do not use it if you have uncontrolled high blood pressure or hypertension with vascular disease. Tell your doctor if you are prediabetic or diabetic, have uncontrolled dyslipidemia, or have significant headaches. Ask your doctor before use if you are pregnant, breastfeeding or have any health concerns.

Frequently asked questions

What is Dinoges-EV used for and what kind of medicine is it?

Dinoges-EV is a combined oral contraceptive tablet. It is used to prevent pregnancy and to treat heavy menstrual bleeding in women without an organic cause who choose an oral contraceptive. It contains a progestin and an estrogen. Your doctor can tell you if it is suitable for you.

Who should avoid Dinoges-EV or ask the doctor first?

Do not use it if you have a high risk of blood clots, undiagnosed abnormal uterine bleeding, or a hormone-sensitive cancer such as breast cancer. Ask your doctor first if you have liver disease, high blood pressure, diabetes, lipid problems, severe headaches, or if you are pregnant or breastfeeding.

What side effects should I watch for and when should I call the doctor?

Common side effects include headache, breast pain, menstrual changes, nausea, acne, mood changes and weight gain. Call your doctor right away if you notice signs of a blood clot such as leg swelling or pain, sudden breathlessness or chest pain, or if any side effect is severe or persistent.

What is the price of Dinoges-EV?

The listed price is ৳ 1680.00.

Indications

This is an estrogen/progestin COC, indicated for use by women to prevent pregnancy. The efficacy of this tablet in women with a body mass index (BMI) of >30 kg/m 2 has not been evaluated. Treatment of heavy menstrual bleeding in women without organic pathology who choose to use an oral contraceptive as their method of contraception.

Pharmacology

COCs lower the risk of becoming pregnant primarily by suppressing ovulation. Other possible mechanisms may include cervical mucus changes that inhibit sperm penetration and endometrial changes that reduce the likelihood of implantation.

Dosage & Administration

Take one tablet daily by mouth at the same time every day. Tablets must be taken in the order directed on the blister pack. Do not skip or delay intake by more than 12 hours. 

Interaction

Drugs or herbal products that induce certain enzymes (for example CYP3A4) may decrease the effectiveness of COCs or increase breakthrough bleeding. Counsel patients to use a back-up or alternative method of contraception when enzyme inducers are used with COCs.

Contraindications

  • A high risk of arterial or venous thrombotic diseases
  • Undiagnosed abnormal uterine bleeding
  • Breast cancer or other estrogens- or progestin-sensitive cancer

Side Effects

The most common adverse reactions (≥2%) in clinical trials for Natazia are headache (including migraines) 13%, breast pain 7%, menstrual disorders 7%, nausea or vomiting 6%, acne 4%, mood changes (3%) and increased weight 3%.

Precautions & Warnings

  • Vascular risks: Stop this tablet if a thrombotic event occurs. Stop this tablet at least 4 weeks before and through 2 weeks after major surgery. Start this tablet no earlier than 4 weeks after delivery, in women who are not breastfeeding.
  • Liver disease: Discontinue this tablet if jaundice occurs.
  • High blood pressure: Do not prescribe this tablet for women with uncontrolled hypertension or hypertension with vascular disease.
  • Carbohydrate and lipid metabolic effects: Monitor prediabetic and diabetic women taking this tablet. Consider an alternate contraceptive method for women with uncontrolled dyslipidemia.
  • Headache: Evaluate significant change in headaches and discontinue this tablet if indicated.
  • Uterine bleeding: Evaluate irregular bleeding or amenorrhea.
  • CYP3A4 induction: Women taking strong CYP3A4 inducers (for example, carbamazepine, phenytoin, rifampicin, and St. John’s wort) should not choose this tablet as their oral contraceptive due to the possibility of decreased contraceptive efficacy.

Storage Conditions

Keep below 30°C temperature, away from light & moisture. Keep out of the reach of children.

Medicine information is for reference only and is not medical advice. Always follow your doctor's prescription and check with a pharmacist.